Fluphenazin-O-decanoat

Bezeichnung:Fluphenazin-O-decanoat

CAS-Nr5002-47-1

Englisch Name:Fluphenazine decanoate

CBNumberCB0260394

SummenformelC32H44F3N3O2S

Molgewicht591.77

MOL-Datei5002-47-1.mol

Synonyma

Fluphenazin-O-decanoat

Fluphenazin-O-decanoat physikalisch-chemischer Eigenschaften

Schmelzpunkt	30-32°
Siedepunkt	658.1±55.0 °C(Predicted)
Dichte	1.149±0.06 g/cm3(Predicted)
storage temp.	Store at -20°C
Löslichkeit	Practically insoluble in water, very soluble in ethanol and in methylene chloride, freely soluble in methanol.
pka	7.32±0.10(Predicted)
CAS Datenbank	5002-47-1

Sicherheit

RIDADR	3249
RTECS-Nr.	HE0525000
HazardClass	6.1(a)
PackingGroup	II

Gefahreninformationscode (GHS)

Fluphenazine decanoate Chemische Eigenschaften,Einsatz,Produktion Methoden

Chemische Eigenschaften
Yellow Oil
Verwenden
Fluphenazine Decanoate is used in psychotropic drug treatments like those relating to schizophrenia. Antipsychotic.
Definition
ChEBI: Fluphenazine decanoate is the prodrug of fluphenazine, an antipsychotic drug used for the symptomatic management of psychosis in patients with schizophrenia. It has a role as a phenothiazine antipsychotic drug, a prodrug and a dopaminergic antagonist. It is a member of phenothiazines, a decanoate ester, an organofluorine compound and a N-alkylpiperazine. It is functionally related to a fluphenazine.
Clinical Use
Antipsychotic
Schizophrenia and other psychoses
Arzneimittelwechselwirkung
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids.
Anti-arrhythmics: increased risk of ventricular arrhythmias with anti-arrhythmics that prolong the QT interval; increased risk of ventricular arrhythmias with amiodarone and dronedarone - avoid; increased risk of ventricular arrhythmias with disopyramide.
Antibacterials: increased risk of ventricular arrhythmias with delamanid and moxifloxacin - avoid
Antidepressants: increased risk of ventricular arrhythmias with tricyclics, citalopram, escitalopram; possible increased risk of convulsions with vortioxetine
Antiepileptics: antagonises anticonvulsant effect.
Antimalarials: increased risk of ventricular arrhythmias with artenimol with piperaquine and artemether/lumefantrine - avoid.
Antipsychotics: increased risk of ventricular arrhythmias with droperidol, pimozide and risperidone - avoid; avoid use of depot formulations with clozapine (cannot be withdrawn quickly if neutropenia occurs).
Antivirals: increased risk of ventricular arrhythmias with saquinavir - avoid; concentration possibly increased with ritonavir.
Anxiolytics and hypnotics: increased sedative effects
Atomoxetine: increased risk of ventricular arrhythmias.
Beta-blockers: enhanced hypotensive effect; increased risk of ventricular arrhythmias with sotalol
Cytotoxics: increased risk of ventricular arrhythmias with arsenic trioxide
Diuretics: enhanced hypotensive effect.
Lithium: increased risk of extrapyramidal side effects and possibly neurotoxicity.
Pentamidine: increased risk of ventricular arrhythmias - avoid.
Avoid with drugs that prolong the QT interval.
Stoffwechsel
The cytochrome P450 isoenzyme CYP2D6 is involved in fluphenazine metabolism.

Fluphenazin-O-decanoat Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

5002-47-1, Fluphenazine decanoate Verwandte Suche:

Send Inquriy